eamdacademy.org-BniV-1792152426-b614851200 1792152426 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2024 3 2 Nguyen Thanh Huy Pham Quang Minh Le Thi Bich 2024 10.68159/b614851200 https://eamdacademy.org/pub/journal/3/article/b614851200 Bannigan P, Aldeghi M, Bao Z, Häse F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. Murray JD, Lange JJ, Bennett-Lenane H, Holm R, Kuentz M, O'Dwyer PJ, et al. Advancing algorithmic drug product development: Recommendations for machine learning approaches in drug formulation. Eur J Pharm Sci. 2023;191:106562. Wang S, Di J, Wang D, Dai X, Hua Y, Gao X, et al. State-of-the-art review of artificial neural networks to predict, characterize and optimize pharmaceutical formulation. Pharmaceutics. 2022;14(1):183. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206-15. Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. Lancet Digit Health. 2021;3(11):e745-50. Guidotti R, Monreale A, Ruggieri S, Turini F, Giannotti F, Pedreschi D. A survey of methods for explaining black box models. ACM Comput Surv. 2018;51(5):93. Liu Q, Huang R, Hsieh J, Zhu H, Tiwari M, Liu G, et al. Landscape analysis of the application of artificial intelligence and machine learning in regulatory submissions for drug development from 2016 to 2021. Clin Pharmacol Ther. 2023;113(4):771-4. Arrieta AB, Díaz-Rodríguez N, Del Ser J, Bennetot A, Tabik S, Barbado A, et al. Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI. Inf Fusion. 2020;58:82-115. Amann J, Blasimme A, Vayena E, Frey D, Madai VI; Precise4Q Consortium. Explainability for artificial intelligence in healthcare: A multidisciplinary perspective. BMC Med Inform Decis Mak. 2020;20(1):310. Lou H, Lian B, Hageman MJ. Applications of machine learning in solid oral dosage form development. J Pharm Sci. 2021;110(9):3150-65. Malheiro V, Duarte J, Veiga F, Mascarenhas-Melo F. Exploiting Pharma 4.0 technologies in the non-biological complex drugs manufacturing: Innovations and implications. Pharmaceutics. 2023;15(11):2545. Ye Z, Yang W, Yang Y, Ouyang D. Interpretable machine learning methods for in vitro pharmaceutical formulation development. Food Front. 2021;2(2):195-207. He Y, Ye Z, Liu X, Wei Z, Qiu F, Li HF, et al. Can machine learning predict drug nanocrystals? J Control Release. 2020;322:274-85. Elbadawi M, Castro BM, Gavins FK, Ong JJ, Gaisford S, Pérez G, et al. M3DISEEN: A novel machine learning approach for predicting the 3D printability of medicines. Int J Pharm. 2020;590:119837. Elbadawi M, McCoubrey LE, Gavins FK, Ong JJ, Goyanes A, Gaisford S, et al. Disrupting 3D printing of medicines with machine learning. Trends Pharmacol Sci. 2021;42(9):745-57. Bao Z, Bufton J, Hickman RJ, Aspuru-Guzik A, Bannigan P, Allen C. Revolutionizing drug formulation development: The increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. Simões MF, Silva G, Pinto AC, Fonseca M, Silva NE, Pinto RM, et al. Artificial neural networks applied to quality-by-design: From formulation development to clinical outcome. Eur J Pharm Biopharm. 2020;152:282-95. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019;151-152:169-90. Elbadawi M, McCoubrey LE, Gavins FK, Ong JJ, Goyanes A, Gaisford S, et al. Harnessing artificial intelligence for the next generation of 3D printed medicines. Adv Drug Deliv Rev. 2021;175:113805. Tjoa E, Guan C. A survey on explainable artificial intelligence (XAI): Toward medical XAI. IEEE Trans Neural Netw Learn Syst. 2021;32(11):4793-813. Struble TJ, Alvarez JC, Brown SP, Chytil M, Cisar J, DesJarlais RL, et al. Current and future roles of artificial intelligence in medicinal chemistry synthesis. J Med Chem. 2020;63(16):8667-82. Ajdarić J, Ibrić S, Pavlović A, Ignjatović L, Ivković B. Prediction of drug stability using deep learning approach: Case study of esomeprazole 40 mg freeze-dried powder for solution. Pharmaceutics. 2021;13(6):829. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdiscip Rev Data Min Knowl Discov. 2019;9(4):e1312. Benjamens S, Dhunnoo P, Meskó B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: An online database. NPJ Digit Med. 2020;3(1):118. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24(3):773-80. Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015–20): A comparative analysis. Lancet Digit Health. 2021;3(3):e195-203. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. In: Hock FJ, Gralinski MR, editors. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Cham: Springer; 2024. p. 1461-98. Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. Intell Med. 2022;2(3):134-40. Volkamer A, Riniker S, Nittinger E, Lanini J, Grisoni F, Evertsson E, et al. Machine learning for small molecule drug discovery in academia and industry. Artif Intell Life Sci. 2023;3:100056.